Hepatotoxicity of Pentavalent Antimonial Drug: Possible Role of Residual Sb(III) and Protective Effect of Ascorbic Acid

Kelly C. Kato,a Eliane Morais-Teixeira,b Priscila G. Reis,a Neila M. Silva-Barcellos,c Pascal Salaün,d Paula P. Campos,a José Dias Corrêa-Junior,a Ana Rabello,c Cynthia Demichelid, Frédéric Frézardb

Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Pampulha, Belo Horizonte, Brazil; Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Pampulha, Belo Horizonte, Brazil; Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Pampulha, Belo Horizonte, Brazil; Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Pampulha, Belo Horizonte, Brazil; Departamento de Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Brazil; School of Environmental Sciences, University of Liverpool, Liverpool, United Kingdom; Laboratório de Pesquisas Clínicas, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Barro Preto, Belo Horizonte, Brazil; CIFarma-Programa de Pós-Graduação em Ciências Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Minas Gerais, Brazil; School of Environmental Sciences, University of Liverpool, Liverpool, United Kingdom; Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Barro Preto, Belo Horizonte, Brazil; School of Environmental Sciences, University of Liverpool, Liverpool, United Kingdom; Department of Pathology, University of Liverpool, Liverpool, United Kingdom; School of Environmental Sciences, University of Liverpool, Liverpool, United Kingdom; School of Environmental Sciences, University of Liverpool, Liverpool, United Kingdom

Pentavalent antimonial drugs such as meglumine antimoniate (Glucantime [Glu; Sanofi-Aventis, São Paulo, Brazil]) produce severe side effects, including cardiotoxicity and hepatotoxicity, during the treatment of leishmaniasis. We evaluated the role of residual Sb(III) in the hepatotoxicity of meglumine antimoniate, as well as the protective effect of the antioxidant ascorbic acid (AA) during antimonial chemotherapy in a murine model of visceral leishmaniasis. BALB/c mice infected with Leishmania infantum were treated intraperitoneally at 80 mg of Sb/kg/day with commercial meglumine antimoniate (Glu) or a synthetic meglumine antimoniate with lower Sb(III) level (MA), in association or not with AA (15 mg/kg/day), for a 20-day period. Control groups received saline or saline plus AA. Livers were evaluated for hepatocytes histological alterations, peroxidase activity, and apoptosis. Increased proportions of swollen and apoptotic hepatocytes were observed in animals treated with Glu compared to animals treated with saline or MA. The peroxidase activity was also enhanced in the liver of animals that received Glu. Cotreatment with AA reduced the extent of histological changes, the apoptotic index, and the peroxidase activity to levels corresponding to the control group. Moreover, the association with AA did not affect the hepatic uptake of Sb and the ability of Glu to reduce the liver and spleen parasite loads in infected mice. In conclusion, our data supports the use of pentavalent antimonials with low residue of Sb(III) and the association of pentavalent antimonials with AA, as effective strategies to reduce side effects in antimonial therapy.

At the beginning of the last century, Gaspar Vianna, pioneer researcher in the treatment of leishmaniasis, reported the efficacy of antimony(III) potassium tartrate (tartar emetic) for treatment of leishmaniasis (1). The less toxic pentavalent antimony [Sb(V)] complexes, including meglumine antimoniate (Glucantime [Glu]), were introduced for the therapy of leishmaniasis from the 1940s. Even though pentavalent antimonials are still the first-line drugs in several countries against all forms of leishmaniasis, their use in the clinical setting has several limitations (2, 3). These compounds have to be given parenterally, daily, for at least 3 weeks (typically, 20 mg of Sb/kg/day for 20 to 30 days). Antimony therapy is often accompanied by local pain during intramuscular injection and by severe side effects that include cardiotoxicity, pancreatitis, hepatotoxicity, and nephrotoxicity (4–8). As consequences, careful medical supervision is required, and compliance problems are common.

The mechanisms involved in the toxicity of pentavalent antimonials are not fully elucidated. However, it is generally accepted that Sb(III), either present as residue in pentavalent antimonials (9) or produced in the tissues through reduction (10), may be responsible for their side effects and antileishmanial action (11). Studies of the mechanism of cytotoxicity of the trivalent tartar emetic drug suggest that Sb(III) compromises thiol homeostasis through depletion of intracellular glutathione and inhibition of glutathione reductase (12, 13). Then, Sb(III) enhances oxidative stress and leads to apoptosis through increase of reactive oxygen species (ROS) (13–15). The toxicity of some batches of pentavalent antimonial drug has also been attributed to contamination with As and Pb (16).

Recently, two new synthetic processes were proposed for meglumine antimoniate (17). One of these methods used K3Sb(OH)6 as a source of antimony, instead of SbCl5, in the commercial process for Glu. This resulted in a more simple method and a final product that exhibited lower in vitro cytotoxicity, compared to Glu (18). It has been suggested that this synthetic meglumine antimoniate may be less toxic in vivo than Glu (11).

Ascorbic acid (AA), known as vitamin C, is an important antioxidant and ROS scavenger which is associated to arsenicals in the treatment of cancer (19–21). Among its several benefits, AA can increase the cytotoxicity of As(III) against multidrug-resistant cells, presumably through reduction of glutathione intracellular concentration (22, 23). AA was also found to reduce the toxicity of arsenicals in rats through the inhibition of oxidative stress (24, 25). Considering the possible role of Sb(III) in the toxicity of pentavalent antimonials and the chemical similarities between Sb(III) and As(III), we hypothesized that AA...

Received 15 July 2013 Returned for modification 16 September 2013 Accepted 27 October 2013 Published ahead of print 4 November 2013

Address correspondence to Frédéric Frézard, frezard@icb.ufmg.br.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.
may reduce the toxicity of pentavalent antimonials during chemotherapy of leishmaniasis.

In the present study, the use of a pentavalent antimonial drug with reduced Sb(III) content and the association of these drugs with AA were investigated as novel strategies for improved therapy of leishmaniasis. More specifically, commercial and synthetic forms of meglumine antimoniate differing in their amount of Sb(III) were compared for their hepatotoxicity and efficacy in a murine model of visceral leishmaniasis (VL). AA also was evaluated for its hepatoprotective effect during pentavalent antimonial chemotherapy and its interference with the drug antileishmanial efficacy.

MATERIALS AND METHODS

Materials. A commercial sample of meglumine antimoniate (Glucantime [Glu]; 5-ml vials at 300 mg/ml, batch 6050 [Sanofi-Aventis, São Paulo, Brazil]) was obtained from the Brazilian Ministry of Health. Ascorbic acid (5-ml vials at concentration of 100 mg/ml; batch 10080785) was obtained from Hypofarma (Ribeirão das Neves, MG, Brazil). N-Methyl-D-glucamine (NMG; 98%), bromopyrogallol red (BPR), and antimony (III) potassium tartrate (tartar emetic) were obtained from Aldrich Chemical Co. (Milwaukee, WI). Potassium hexahydroxoantimoniate [KSB(OH)₆] was obtained from Fluka Chemie GmbH (Switzerland). Synthetic meglumine antimoniate (MA) was obtained from the reaction of NMG with KSB (OH)₆, as previously described (17). The total antimony concentration in MA and Glu, as determined by atomic absorption spectroscopy, was ca. 30% (wt/wt).

Trace metal analysis in pentavalent antimonials. The traces of Pb and As were assayed in the antimonial drugs using a Perkin-Elmer NexION 300 ICP-MS apparatus. The procedures used to determine Sb(III) were described in detail previously (9, 18). The photometric method is based on the specific interaction of Sb(III) with the chromogen BPR. The absorbance of BPR at 560 nm decreases proportionally to the amount of Sb(III) in the analyte solution, as a consequence of the formation of a 1:1 BPR-Sb(III) complex. Briefly, 0.5 ml of analyte solution was prepared from 0.1 ml of 0.1 M phosphate, 0.01 ml of 5% (wt/vol) tartrate, 0.05 ml of 350 μM BPR solution in a 1:1 water-ethanol (vol/vol) mixture and 0.34 ml of water. The pH was then adjusted to 6.8 by using sodium hydroxide. The absorbance was registered at 560 nm before (A₀) and after (Aₙ) adding 5 μl of the sample to be analyzed. For each experiment, a calibration curve was established by using tartar emetic as the source of Sb(III) and plotting the difference in the absorbance (Aₙ − A₀) as a function of Sb(III) concentration.

The voltammetric method is based on anodic stripping voltammetry at a gold wire electrode and was described in detail recently (9) for 20 days: (i) Glu group, Glu at 80 mg of Sb/kg/day; (ii) MA group, MA at 80 mg of Sb/kg/day; (iii) Glu + AA group, Glu at 80 mg of Sb/kg/day and ascorbic acid at 15 mg/kg/day given 15 min before antimonial drug; (iv) MA + AA group, MA at 80 mg of Sb/kg/day and ascorbic acid at 15 mg/kg/day; (v) AA group, ascorbic acid at 15 mg/kg/day; and (vi) saline group, isotonic saline.

The choice of AA dose was based on the 250-μg/kg dose given daily by oral route which promoted hepatoprotection in rats exposed for 30 days to arsinite trioxide (24). Conversion of the oral dose to an i.p. dose was made, considering that an oral dose of 250 mg/kg would produce a peak plasma concentration close to that of an i.p. dose of 8 mg/kg in rats (26), which in turn would be equivalent to 16 mg/kg in mice.

Animals and parasites. BALB/c mice (female, 4 to 6 weeks old, 18 to 22 g) were obtained from the Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz-Fiocruz (CPqRR; Belo Horizonte, MG, Brazil). Free access was allowed to standard diet and tap water was supplied ad libitum. Leishmania infantum promastigotes of strain MHOM/BR/70/BI46, originally obtained from the CPqRR, were maintained in vitro at 22 ± 1°C in Schneider’s medium supplemented with 10% bovine fetal serum by serial subcultures after every 48 to 72 h.

Infection of animals and treatment protocol. BALB/c mice were inoculated through the tail vein with 2 × 10⁷ of L. infantum promastigotes/200 μl, obtained after 8 days of culture growth. Infected animals were divided into six groups (n = 7), and treatment was initiated 7 days after infection with the following preparations given daily intraperitoneally (i.p.) for 20 days: (i) Glu group, Glu at 80 mg of Sb/kg/day; (ii) MA group, MA at 80 mg of Sb/kg/day; (iii) Glu + AA group, Glu at 80 mg of Sb/kg/day and ascorbic acid at 15 mg/kg/day given 15 min before antimonial drug; (iv) MA + AA group, MA at 80 mg of Sb/kg/day and ascorbic acid at 15 mg/kg/day; (v) AA group, ascorbic acid at 15 mg/kg/day; and (vi) saline group, isotonic saline.

The peroxidase activity was measured as a % decrease in absorbance at 470 nm after addition of 0.25 ml of 1 M HCl to 0.2 ml of an ethanolic solution of peroxidase at 1 mg/ml. The peroxidase activity was measured as a % decrease in absorbance at 470 nm after addition of 0.25 ml of 1 M HCl to 0.2 ml of an ethanolic solution of peroxidase at 1 mg/ml. The peroxidase activity of liver was measured as a % decrease in absorbance at 470 nm after addition of 0.25 ml of 1 M HCl to 0.2 ml of an ethanolic solution of peroxidase at 1 mg/ml.
Apoptosis in the liver. Apoptotic cells were first detected by the observation of cell morphology changes and counted to estimate the apoptotic event, as previously described (34, 35). The analysis was performed on scanned images with a ×40 panchromatic objective lens, selecting the central regions, and avoiding necrosis areas, using the software Sigma Scan Pro 5 imaging program. Apoptosis was further evaluated semiquantitatively by the TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling) method (36) in paraffin-embedded sections mounted on glass slides using a commercial kit (FragEL DNA fragmentation detection kit; Colorimetric-Calbiochem), according to the manufacturer’s instructions.

Cells were considered positive when they showed strong nuclear staining, recognized by the presence of dark brown lumps and at least one of the following morphological criteria: (i) anoikis (cell shrinkage with loss of adhesion with adjacent cells), (ii) nuclear condensation (condensed chromatin, sometimes partially permeating the nuclear membrane forming crescent figures), (iii) fragmentation of the nuclear and cytoplasmic membrane (without karyorrhexis or rupture), or (iv) formation of apoptotic bodies resulting from cell fractionation. Positive hepatocytes were then counted blindly, and results were expressed as a percentage of the total hepatocytes, excluding the surrounding massive necrosis lesion. The apoptotic index, i.e., the total number of cells with apoptosis/total number of cells × 100, was determined in 15 fields per slide.

Statistical analysis. Comparison of the results obtained between different experimental groups was performed using Kruskal-Wallis test (followed by Dunn’s multiple comparison test) or Mann-Whitney test in the case of data with non-normal distribution. Comparison between normally distributed data was performed by one-way analysis of variance (ANOVA) with the Bonferroni post test. Differences with P values of <0.05 were considered statistically significant.

RESULTS

Sb(III) content in pentavalent antimonial compounds. Two different forms of meglumine antimoniate were evaluated: the commercial form (Glu) and meglumine antimoniate (MA) synthesized from KSB(OH)₆ (17). Trace metal analysis did not show detectable levels of Pb (<2.5 µg/g) or As (<1.5 µg/g) in either Glu or MA. On the other hand, residual Sb(III) could be detected by two different methods: a recently developed voltammetric method (9) and a photometric method based on the specific interaction of Sb(III) with BPR chromogen (18). Although Glu and MA have similar total Sb levels (30% [wt/wt]), Glu had a higher content of Sb(III) compared to MA. Interestingly, Sb(III) showed much higher availability in the voltammetric than in the photometric assay. According to the voltammetric method, Glu and MA showed, respectively, 24.1% ± 0.4% and 16.3% ± 0.7% of Sb(III) in relation to total Sb. In agreement with our previous report (18), the photometric method showed Sb(III) proportion of 0.068% ± 0.002% in Glu and did not detect significant level of Sb(III) in MA (proportion < 0.007%).

Antileishmanial activity and hepatotoxicity of pentavalent antimonial compounds in a murine model of visceral leishmaniasis. BALB/c mice experimentally infected with L. infantum underwent chemotherapy with Glu or MA at the same dose of total antimony of 80 mg/(kg day) for 20 days by the i.p. route. Three days after the end of treatment, the animals were sacrificed, and the parasite burdens were evaluated in the liver and spleen. As shown in Fig. 1, significant reductions of liver and spleen parasite loads were observed in the groups treated with both antimonial drugs compared to the control group treated with saline. No significant difference in parasite load was encountered between Glu and MA groups. In accordance with this result, similar concentrations of Sb were found in the livers of mice after treatment with Glu and MA (4.2 ± 1.0 versus 4.9 ± 1.0 µg/g of wet liver).

The hearts, kidneys, pancreases, spleens, and livers were evaluated for histopathological changes after treatment, and comparison was also made between infected and noninfected control groups. Heart, kidney, pancreas, and spleen samples did not show significant histological changes upon treatment with Glu or MA (data not shown). On the other hand, histopathological changes were observed in the liver. As illustrated in Fig. 2D, the hepatocytes of the Glu group showed vacuolization and granulosity in contrast to those of control and MA groups. Figure 3A shows the result of quantification of lucent areas, indicating a significant increase after treatment with Glu. Since PAS evaluation was negative (data not shown), this change could be attributed to alteration in water homeostasis, which may be caused by free radicals. Further evidence of hepatotoxicity in Glu group was obtained from the increase of TUNEL-positive hepatocytes (Fig. 2A) and of the apoptotic index (Fig. 3B).

It is noteworthy that the group treated with MA, in contrast to Glu group, did not show significant histological changes and increases in apoptotic activity (Fig. 2B, 2E, and 3B) compared to the control. These data suggest that Sb(III) present at a higher level in Glu is responsible for the hepatotoxicity.

In accordance with this model, treatment with Glu, but not MA, significantly increased the peroxidase activity in the hepatic tissue, as evidenced by the greater level of conversion of DAB substrate (Fig. 3C). These data suggest an increased oxidative stress in the liver upon treatment with Glu.
Hepatoprotective effect of ascorbic acid in mice treated with Glu. AA was evaluated in association with Glu for its ability to reduce hepatotoxicity in the murine model of VL. An experimental group received Glu at 80 mg of Sb/kg plus AA at 15 mg/kg daily for 20 days, and comparison was made with experimental groups treated with either Glu, AA, or saline. As shown in Fig. 4, cotreatment with AA (the Glu/A group) reduced the lucent area of hepatocytes (Fig. 4A) and the apoptotic index (Fig. 4B) to an extent similar to that observed in saline-treated animals. The reduction of oxidative stress following cotreatment with AA was supported by the decrease of peroxidase activity compared to treatment with Glu alone (Fig. 4C).

In order to verify that the reduced histological alterations in Glu/A group were not due to a lower uptake of Sb in the liver, the amount of Sb in the liver was compared between the Glu and the Glu/A groups. A similar value of ∼4 μg of Sb/g of wet tissue was found in both groups.

Interference of ascorbic acid with the antileishmanial efficacy of Glu. Since antimonial drugs seem to exert their activity against *Leishmania* parasite through the induction of oxidative stress (12, 37, 38), it was also important to evaluate the level of interference of the antioxidant AA on the efficacy of Glu. As shown in Fig. 5, the extent of parasite suppression in the liver did not differ significantly between AA and the Glu groups. On the other hand, the association of AA with Glu improved the efficacy of the antimonial drug with regard to parasite suppression in the spleen. Thus, cotreatment with AA slightly increased the effectiveness of Glu in this VL model. In the case of MA, cotreatment with AA had no significant effect on the parasite suppressions in both the liver and the spleen (data not shown).

**DISCUSSION**

The present study reports for the first time a murine model of Glu-induced hepatotoxicity, based on histopathological changes and the increase of apoptotic index of hepatocytes. The observed changes are consistent with previous reports of histological alterations in the liver of nonhuman primate (39), elevation of serum level of hepatic enzymes (2–4), and hepatic failure (5) during pentavalent antimonial chemotherapy. The fact that among the different organs evaluated only the liver showed significant histopathological changes may be explained by the pharmacokinetics of meglumine antimoniate leading to elevated concentration of Sb in the liver (40).

Considering that toxic As and Pb metals were not detected by ICP-MS in the antimonial drugs and that MA with lower Sb(III) residue generated virtually no hepatotoxicity, one can reasonably assume that the hepatotoxicity of Glu is due to residual Sb(III) and its higher bioavailability from this antimonial compound. The apparently lower bioavailability of Sb(III) from MA is consistent with our previous study (18) showing a much lower cytotoxicity of this compound against a tumor cell line compared to Glu.

The proposal that residual Sb(III) in Glu promoted hepatotoxicity is consistent with the high dose of Sb(III) administered, which corresponds to ∼20 mg of Sb(III) per kg of body weight, based on 24% proportion of antimony under the trivalent form. Indeed, previous study of the subchronic toxicity of antimony(III) potassium tartrate in mice by the i.p. route revealed hepatocellular necrosis following 12 daily doses of 18 mg of Sb(III)/kg (41).

The discrepancy between Sb(III) concentrations determined by the different analytical methods is probably due to a combination of several experimental and/or chemical factors that promote a relatively strong complexation of Sb(III) to the meglumine antimoniate matrix in the photometric assay compared to the voltammetric assay: a higher pH value (pH 6.8 versus 3.2 for voltammetry), a much lower dilution factor for the BPR method (10^6 versus 10^7), and a higher ionic strength (20 versus 1 mM). These parameters (pH, dilution factor, and ionic strength) were all previously shown to have a significant

**FIG 2** Histopathology (D to F) and apoptosis (A to C) analysis in the livers of *L. infantum*-infected BALB/c mice treated as follows: A and D, Glu, given i.p. at 80 mg of Sb/kg/day; B and E, MA, given i.p. at 80 mg of Sb/kg/day; or C and F, saline, given i.p. Histology was evaluated by H&E staining. Apoptosis was assessed by TUNEL. Cells were considered positive when they showed a strong nuclear staining recognized by the presence of dark brown lumps and morphological changes characteristic of apoptosis (see Materials and Methods for details). Bar, 20 μm.
influence on the level of Sb(III) determined in Glu (9). In that study, the amount of Sb(III) detected was shown to decrease markedly at higher pH, presumably because of pH-induced change in the chemical equilibrium of antimony complex(es) in solution. In addition, although the sample was diluted up to 10^8-fold at neutral pH (\(\times 10^8\)), Sb(III) was still present as a complex, highlighting the strong complexation constant between Sb(III) and meglumine/meglumine antimoniate ligand (9). In the present work, the BPR assay is based on the competition between BPR and the meglumine/meglumine antimoniate ligand for Sb(III) binding. Thus, the much lower concentrations of Sb(III) detected by this method may be attributed to a relatively high pH value (6.8) and low dilution factor, which favored strong complexation of Sb(III) with the meglumine/meglumine antimoniate ligand and consequently decreased the amount of Sb(III)-BPR complex.

The induction of peroxidase activity in the livers of mice treated with Glu is also in agreement with the role of Sb(III) in

FIG 3 Effect of treatment of \(L.\ infantum\)-infected BALB/c mice with commercial (Glu) or synthetic (MA) meglumine antimoniate using different liver parameters: A, lucent area in hepatocytes; B, apoptotic index of hepatocytes; and C, peroxidase activity. Mice were treated with Glu or MA (80 mg of Sb/kg/day) or saline for 20 days by the i.p. route. Noninfected mice receiving saline were also used as controls. The data are means ± the standard errors of the mean (SEM; \(n = 3\) to 7). ***, \(P < 0.001\) (one-way ANOVA with Bonferroni post test).

FIG 4 Influence of AA on the liver parameters of \(L.\ infantum\)-infected BALB/c mice treated or not to with commercial meglumine antimoniate (Glu). The liver parameters measured included the percentage of lucent area in the hepatocytes (A), the apoptotic index of the hepatocytes (B), and the peroxidase activity (C). Mice were treated with Glu (80 mg/kg/day), AA (15 mg/kg/day), Glu + AA, or saline alone for 20 days by the i.p. route. Data are means ± the SEM (\(n = 3\) to 7). ***, \(P < 0.001\); **, \(P < 0.01\) (one-way ANOVA with Bonferroni post test).
the mechanism of toxicity of this pentavalent antimonial drug (11, 18). Indeed, the interference of Sb(III) with the thiol homeostasis (13) results in the increase of ROS production, oxidative stress, and the induction of peroxidase activity and apoptosis (42, 43).

It is generally accepted that pentavalent antimonials are prodrugs that suffer reduction in vivo from Sb(V) to Sb(III) (10, 11). However, the recent observation that Glu contains high amounts of residual Sb(III) (9) led us to propose an alternative model, in which meglumine antimoniate may act as molecular carrier of Sb(III) and release it specifically in the acidic intracellular compartment where Leishmania parasite resides. Both models assume that Sb(III) is the final active form against the parasite. This interpretation is also consistent with the finding that pentavalent antimonials are active against axenic amastigotes grown at pH 5.5 but relatively inactive against Leishmania promastigotes grown at pH 7 (12).

The demonstration that cotreatment with AA protects the liver against pentavalent antimonial drug toxicity is an important contribution of the present work. This effect may be attributed to the ability of AA to act as secondary defense against oxidative stress. Although a similar effect of AA was previously reported in the case of As(III)-based drug (24, 25), this is the first demonstration of a beneficial effect of AA for a metalloid drug in the pentavalent state. These data strongly suggest that cotreatment with AA may be able to reduce side effects in antimonial chemotherapy. Even though the demonstration of the protective effect of AA is limited to the liver, we expect that in future studies this effect will be extended to other critical organs such as the heart, pancreas, and kidney.

Surprisingly, AA was found to improve the antileishmanial efficacy of Glu. As a possible explanation, AA may reduce the intracellular thiol concentration of Leishmania parasite, as previously reported in multidrug-resistant tumor cells (21, 22), turning the antimonial drug more active (44). One should also consider that AA may exert either an antioxidant or a pro-oxidant activity, depending on the concentration and experimental conditions (45). It is noteworthy that the dose of AA used in our study was ~10-fold lower than the effective dose of AA in the treatment of multiple myeloma in combination with arsenic trioxide, which exploits AA pro-oxidant activity (19, 20). Thus, we suggest here the coexistence of two opposite actions of AA that may take place in distinct cellular compartments: an antioxidant action reducing the drug side effects and a pro-oxidant action enhancing the drug efficacy. In conclusion, our data support the use of pentavalent antimonials with low amount of Sb(III) and the association of pentavalent antimonials with AA as effective strategies for minimizing the side effects mediated by oxidative stress during antimonial therapy.

ACKNOWLEDGMENTS

We acknowledge the Brazilian agencies CNPq (303046/2009 and a studentship), FAPEMIG (PPM-00382-11, REDE 40/11, and CBB-APQ-01123-09), and CAPES (2447/2009 and a studentship) for financial support. F.F. and C.D. are recipients of a research fellowship from CNPq.

REFERENCES


